Evidence map›Paper›PMID 41221286›Full record

ArticleFrontiers in immunology2025

Prolonged skin allograft survival by rM180 amelogenin in a murine skin transplantation model.

Miyu Shida, Terukazu Sanui, Karen Yotsumoto, Jinfeng Li, Mwannes Ahmad, Meng Xiao, Ziyu Wang, Chikako Hayashi, Yuki Nishimura, Takanori Shinjo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Miyu ShidaDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Terukazu SanuiDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Karen YotsumotoDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Jinfeng LiDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Mwannes AhmadDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Meng XiaoDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Ziyu WangDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Chikako HayashiDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Yuki NishimuraDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Takanori ShinjoDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Takaharu TaketomiDental and Oral Medical Center, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Takao FukudaDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
Fusanori NishimuraDepartment of Periodontology, Division of Oral Rehabilitation, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Amelogenin, used as a periodontal tissue regeneration material, promotes healing after periodontal surgery. A previous study has demonstrated that amelogenin is taken up by macrophages into the nucleus and inhibits major histocompatibility class II (MHC II) expression at the transcriptional level, thereby suppressing subsequent T cell activation. Therefore, in this study, we focused on the suppressive effect of amelogenin on MHC II expression and examined the effect of amelogenin on graft rejection following allogeneic skin transplantation in mice with different MHC II haplotype antigens. Methods and results: Skin grafts were treated with recombinant murine amelogenin (rM180) and transplanted into recipient mice. The rM180-treated group showed a significant increase in graft survival for up to 5.5 days and a lower necrotic score than the control group. Inflammatory cell infiltration and MHC II Discussion: These results may suggest that amelogenin can be a safe immunosuppressant or therapeutic agent against autoimmune diseases without inducing unfavorable side effects.

Indexed as

AmelogeninGraft RejectionGraft SurvivalSkin TransplantationAllograftsAnimalsCytokinesDisease Models, AnimalHistocompatibility Antigens Class IIMaleMiceMice, Inbred BALB CMice, Inbred C57BLRecombinant ProteinsTransplantation, HomologousAmelogeninCytokinesHistocompatibility Antigens Class IIRecombinant Proteinsallogeneic skin transplantationamelogeninimmunosuppressionM2 macrophagesRNA sequencing analysisTh17/Treg balanceTh1 cells

Identifiers

PMID41221286
PMCPMC12597935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.